Abstract
Abstract
Background
Polycystic Ovarian Syndrome (PCOS) is a multifaceted endocrinopathy affecting women, typically characterized by chronic ovulation dysfunction, hyperandrogenism, and metabolic anomalies including insulin resistance (IR), dyslipidemia, endothelial dysfunction, and systemic inflammation. Numerous strategies have been explored to alleviate PCOS symptoms, but treatment-resistant cases still exist. This study aimed to assess the combined effects of vitamin C, chromium, magnesium, and metformin administration on the metabolic, inflammatory, and hormonal profiles of PCOS patients.
Methods
A descriptive placebo-controlled clinical trial enrolled 77 women aged 18–40 diagnosed with PCOS with no effective response to standard and common treatment protocols. Each participant underwent clinical, biochemical, and ultrasonographic assessments before and after the supplementation. Initially, they were categorized into intervention and placebo groups based on the HOMA-IR index and serum magnesium levels using random block allocation. The intervention group received daily doses of 2000 mg of vitamin C, 375 mg of magnesium (if magnesium deficiency was present), 200 µg of chromium, and 500 mg of metformin. Descriptive statistical analyses were conducted using IBM Statistical Package for Social Sciences version 27.0 (SPSS, Inc., Chicago, IL, USA).
Results
Comparing data at the end of the study with baseline and placebo data, significant improvements were observed in serum carbohydrate parameters (fasting blood sugar (FBS), insulin, and IR), lipid profiles (total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)), and hormonal levels (prolactin, testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol) (P < 0.05). Additionally, there was a noteworthy reduction in the mean level of the inflammatory marker C-reactive protein (CRP) following supplementation (P < 0.05).
Conclusions
This study suggests that our combination supplement regimen can effectively enhance biochemical, inflammatory, and hormonal indicators in PCOS-positive women, potentially resulting in ovaries free of cysts.
Publisher
Research Square Platform LLC
Reference72 articles.
1. Polycystic Ovarian Syndrome: Prevalence, Predisposing Factors, and Awareness Among Adolescent and Young Girls of South India;Jabeen A;Cureus,2022
2. An update of polycystic ovary syndrome: causes and therapeutics options;Rababa'h AM;Heliyon,2022
3. Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews;Gilbert EW;Clin Endocrinol (Oxf),2018
4. Fiorentino G, Cimadomo D, Innocenti F, Soscia D, Vaiarelli A, Ubaldi FM, Gennarelli G, Garagna S, Rienzi L, Zuccotti M. Biomechanical forces and signals operating in the ovary during folliculogenesis and their dysregulation: implications for fertility. Hum Reprod Update. 2023;29(1):1–23. 10.1093/humupd/dmac031. PMID: 35856663.
5. Downregulation of Extracellular Matrix and Cell Adhesion Molecules in Cumulus Cells of Infertile Polycystic Ovary Syndrome Women with and without Insulin Resistance;Hassani F;Cell J,2019